Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Newly Identified Dynactin Variant (DCTN1 p.Tyr78His) in a Patient with Perry Syndrome
Movement Disorders
P13 - Poster Session 13 (5:30 PM-6:30 PM)
3-007

To describe a person with Perry Syndrome (PS) that carries a novel Tyr78His DCTN1 variant and propose expansion of pathogenic PS genetic variants. 

PS is a rare hereditary neurodegenerative disease characterized by autosomal dominant Parkinsonism, psychiatric symptoms, central hypoventilation and weight change. Nine missense mutations in exon 2 of DCTN1 and one intronic splice mutation MAPT genes have been found to be pathogenic.

Sequence analysis via FTD/ALS/PD panel on 38 genes and C9orf72 deletion/duplication testing performed by Invitae (San Francisco, CA).

Fifty-seven year-old adopted male with history of erectile dysfunction, apathy, knee replacement complicated by septic arthritis presented with three years of progressive imbalance, bradykinesia, shuffling gait, depression, fatigue, concentration difficulties, perseveration and falls. Exam revealed masked facies, impaired vertical pursuits, delayed movements/speech, decreased arm swing, minimal episodic tremor, relatively spared memory and preserved sense of smell. Symptoms did not respond to carbidopa/levodopa. Within months he developed refractory recurrent hypercarbic respiratory failure due to nocturnal central hypoventilation, which eventually required tracheostomy and scheduled nocturnal positive pressure ventilation. Patient’s weight loss was reversed after tracheostomy.

Serum evaluation confirmed nocturnal hypercarbia. EMG, MRI, EEG, and CSF analysis (including paraneoplastic panel, VGCC and IgLON5 antibodies) failed to explain central nocturnal hypopnea. Genetic testing revealed Tyr78His DCTN1 variant of unknown significance, which had never been described in healthy or affected individuals. In silico analyses suggested pathogenicity. Tyr78His disrupts hydrophobic cluster near Tyr78 similarly to Tyr78Cys, a recognized pathogenic variant. Segregation analysis could not be performed given patient’s adopted status.

We argue Tyr78HIS DCTN1 variant is the tenth pathogenic missense mutation causing PS; based on our patient’s phenotype, the mutation’s similarity to known pathogenic variant at the same codon and concordant in silico results. This case broadens the understanding of genetic variants of PS and thereby contributes to diagnosis of this seldom recognized genetic disorder.

Authors/Disclosures
Marek Cierny, MD (Medical College of Wisconsin)
PRESENTER
No disclosure on file
Sam Hooshmand, DO (Medical College of Wisconsin) Dr. Hooshmand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genetech USA. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics . Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech USA. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TG Therapeutics . Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen . The institution of Dr. Hooshmand has received research support from Novartis .
Dominic B. Fee, MD, FÂé¶¹´«Ã½Ó³»­ (Medical College of Wisconsin) An immediate family member of Dr. Fee has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for The Spine Journal. The institution of Dr. Fee has received research support from ALS Association. The institution of an immediate family member of Dr. Fee has received research support from Veterans Administration.
Ryan T. Brennan, DO (Medical College of Wisconsin) Dr. Brennan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie.